干细胞移植作为难治性克罗恩病细胞疗法的修复性免疫学后果
这项II期研究纳入19例对现有药物无效的活动性克罗恩病成人患者,纵向采集血液和肠道样本,用CyTOF和单细胞RNA测序分析干细胞移植后的免疫重建,并将患者造血干细胞用于小鼠异种移植模型进行功能检测。结果显示移植主要影响肠道髓系细胞,炎性细胞群减少,支持黏膜愈合的巨噬细胞恢复;异种移植模型提示患者造血干细胞支持髓系早期重建,但短期和长期植入受损,可能决定移植结局。作者认为干细胞移植是一种靶向髓系的细胞疗法,凸显巨噬细胞在难治性克罗恩病病理生理中的关键作用,并报告了克罗恩病中造血干细胞亚群未被认识的功能异质性。
要点
- 干细胞移植后肠道炎性髓系细胞群减少,支持黏膜愈合的巨噬细胞恢复。
- 异种移植模型提示患者造血干细胞短期和长期植入受损,可能决定移植结局。
- 作者认为干细胞移植是靶向髓系的细胞疗法,巨噬细胞是难治性克罗恩病的治疗靶点。
核心结论
- 本研究提示干细胞移植发挥靶向髓系的细胞疗法作用,强化巨噬细胞在难治性克罗恩病病理生理中的关键作用及其作为细胞治疗靶点的地位。
- 作者报告克罗恩病中造血干细胞亚群存在未被认识的功能异质性,可能与对克罗恩病治疗和病理生理的理解相关。
研究设计与样本
- II期研究纳入19例临床和内镜下活动、现有药物治疗失败的成人克罗恩病患者,接受自体造血干细胞移植。
- 纵向采集血液和肠道样本,采用CyTOF和单细胞RNA测序分析;患者干细胞自体移植物在小鼠异种移植模型中进行功能检测。
主要发现
- 单细胞RNA测序和CyTOF分析显示,干细胞移植主要影响肠道髓系谱系,炎性细胞群减少,能够支持黏膜愈合的巨噬细胞恢复。
- 使用患者造血干细胞的小鼠异种移植模型提示,造血干细胞支持髓系谱系的早期重建,并揭示短期和长期造血干细胞植入受损,可能决定干细胞移植结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment strategies for Crohn's disease (CD) suppress diverse inflammatory pathways but many patients remain refractory to treatment. Autologous haematopoietic stem cell transplantation (SCT) is an emerging therapy for medically refractory CD though the mechanisms through which it circumvents refractory pathophysiology are unknown. OBJECTIVE: The objective of this study is to understand how the immune system reconstitutes post-SCT and whether SCT may function as a cellular therapy restoring appropriately responsive immune cell populations from haematopoietic stem cells (HSCs). DESIGN: Adults with CD with active clinical and endoscopic disease who failed available medical therapies were enrolled in a phase II study of SCT for refractory CD (n=19). Blood and intestinal samples were collected longitudinally and analysed using CyTOF and scRNA-seq. Stem cell autografts were functionally assayed in mouse xenograft models. RESULTS: scRNA-seq and CyTOF analyses reveal that SCT predominantly affected the intestinal myeloid lineage with loss of inflammatory populations and return of macrophages capable of supporting mucosal healing. Xenograft models using patient HSCs suggested that HSCs support the early reconstitution of the myeloid lineage and reveal an impairment of short and long-term HSC engraftment that may determine SCT outcomes. CONCLUSIONS: This study suggests SCT functions as a myeloid-directed cellular therapy reinforcing the critical role of macrophages in refractory CD pathophysiology and as a target for cellular therapies. Furthermore, we report an unrecognised functional heterogeneity among HSC subpopulations in CD that may be relevant to our understanding of CD treatment and pathophysiology.
引用
- Guisado D, Talware S, Wang X, et al. Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease. Gut. 2025. PMID: 39961646. doi:10.1136/gutjnl-2024-333558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。